SCHEMBL3362372

SCHEMBL3362372

C[CH]Cc1ccc(O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.50
ESR2 Q92731 3/20 0.50
ABAT P80404 1/20 0.46
LMNA P02545 3/20 0.44
CYP3A4 P08684 3/20 0.44
HIF1A Q16665 3/20 0.44
HSD17B10 Q99714 3/20 0.44
ADORA3 P0DMS8 3/20 0.44
CYP2C19 P33261 2/20 0.44
CA2 P00918 2/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
ALOX15 P16050 2/20 0.44
KMT2A Q03164 2/20 0.44
TP53 P04637 2/20 0.44
NR3C1 P04150 1/20 0.44
CYP1A2 P05177 1/20 0.44
GAA P10253 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9154630 0.86 ALDH1A1 (0.39) CYP3A4ALOX15TP53ALOX12ALDH1A1
SCHEMBL111720 0.80 IDO1 (0.50) ESR1ESR2ABATLMNACYP3A4
SCHEMBL13743996 0.80 IDO1 (0.50) ESR1ESR2ABATLMNACYP3A4
SCHEMBL111719 0.80 IDO1 (0.50) ESR1ESR2ABATLMNACYP3A4
SCHEMBL448422 0.78 ESR1 (0.55) ESR1ESR2ABATLMNACYP3A4
SCHEMBL448421 0.78 ESR1 (0.55) ESR1ESR2ABATLMNACYP3A4
SCHEMBL105690 0.76 ESR1 (0.52) ESR1ESR2ABATLMNACYP3A4
SCHEMBL9249830 0.76 TP53 (0.46) LMNACA2TP53CYP2C9TAAR1
SCHEMBL3805915 0.76 ESR1 (0.52) ESR1ESR2ABATLMNACYP3A4
SCHEMBL3465880 0.76 IDO1 (0.48) LMNACA2MAPTTP53CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383637-B2 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) JANSSSEN PHARMACEUTICA N.V. (BE) 2013-02-26 US claimed
EP-1776349-B1 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA NV (BE) 2010-10-06 EP claimed
CN-101035771-A 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA NV (BE) 2007-09-12 CN claimed
EP-1776349-A2 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-25 EP claimed
US-20060079687-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-13 US claimed
WO-2006017836-A2 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-02-16 WO claimed
US-5364948-A Anticancer, anticholesterol, fungicide MERCK & CO., INC. (US) 1994-11-15 US claimed
US-5049587-A Mabuterol BASOTHERM GMBH (DE) 1991-09-17 US claimed
US-4119710-A ANALGESICS, UTEROSPASMOLYTICS, ANTISPASTICS, BLOCKING AGENTS BOEHRINGER INGELHEIM GMBH (DE) 1978-10-10 US claimed
US-3996383-A 3-Alkylamino-α-aminomethyl-4-hydroxybenzyl alcohols with β-adrenergic stimulant activity SMITHKLINE CORPORATION (US) 1976-12-07 US claimed
US-3943173-A 3-Alkylamino- alpha-aminomethyl-4-hydroxybenzyl alcohols SMITHKLINE CORPORATION (US) 1976-03-09 US claimed
US-11149028-B2 Methods for treating melanoma using small molecules NOVA SOUTHEASTERN UNIVERSITY (US) 2021-10-19 US disclosed
EP-3849311-A1 FUNGICIDAL HALOMETHYL KETONES AND HYDRATES FMC Corporation (US) 2021-07-21 EP disclosed
WO-2020056090-A1 FUNGICIDAL HALOMETHYL KETONES AND HYDRATES FMC CORPORATION (US) 2020-03-19 WO disclosed
US-20200062736-A1 METHODS FOR TREATING MELANOMA USING SMALL MOLECULES AND SMALL INTERFERING RNA (siRNA) NOVA SOUTHEASTERN UNIVERSITY (US) 2020-02-27 US disclosed
US-4001421-A THIAZOLE CARDIOVASCULAR AGENTS SYNTEX (U.S.A.) INC. (US) 1977-01-04 US disclosed
US-3996383-A 3-Alkylamino-α-aminomethyl-4-hydroxybenzyl alcohols with β-adrenergic stimulant activity SMITHKLINE CORPORATION (US) 1976-12-07 US disclosed
US-3982010-A Thiazole cardiovascular agents SYNTEX (U.S.A.) INC. (US) 1976-09-21 US disclosed
US-3978041-A CARDIAC INSUFFICIENCY CIBA-GEIGY CORPORATION (US) 1976-08-31 US disclosed
US-3943173-A 3-Alkylamino- alpha-aminomethyl-4-hydroxybenzyl alcohols SMITHKLINE CORPORATION (US) 1976-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149028-B2 Methods for treating melanoma using small molecules DDX1, HNRNPH3, HNRNPA2B1 ESR1 2902/4885ESR2 1684/4885ABAT 4507/4885
US-20060079687-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) BACE2, BACE1, APP ESR1 3103/4885ESR2 1446/4885ABAT 401/4885
US-20200062736-A1 METHODS FOR TREATING MELANOMA USING SMALL MOLECULES AND SMALL INTERFERING RNA (siRNA) HNRNPH3, DDX1, HNRNPH1 ESR1 2831/4885ESR2 1838/4885ABAT 4418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.